Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1989 Oct;3(5):731-42.
doi: 10.1007/BF01857623.

Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia

Affiliations
Review

Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia

R Massingham et al. Cardiovasc Drugs Ther. 1989 Oct.

Abstract

In this review the pharmacologic properties of the calcium antagonist bepridil have been reexamined, particularly the evidence for an intracellular locus of action for the drug. Physicochemical properties of bepridil show it to be highly lipophylic, rapidly and extensively taken up, and accumulated in certain tissues. Combined electrophysiologic and mechanical studies have provided convincing, but indirect, evidence for an intracellular action of bepridil in cardiac muscle. Bepridil also fulfills, to a greater or lesser extent, certain important pharmacologic criteria necessary for evoking an intracellular action of a drug in cardiac and vascular smooth muscle: 1. Responses to agonists known to utilize intracellular calcium in the response are inhibited to a similar extent to depolarization-induced K+ responses. 2. Phasic and tonic responses to noradrenaline in vascular tissues are not, or are only to a minor extent, differentially antagonized. 3. Responses to the calcium ionophore A 23187 are antagonized. 4. Activity is retained following removal of the cell membrane by surfactants. 5. Isolated enzyme systems (e.g., calmodulin, myosin light-chain kinase) are affected by the drug at similar concentrations to those that are effective in whole cells or tissues. Finally results obtained with bepridil in ischemic myocardium have been reviewed to ascertain whether its broader pharmacologic spectrum over the calcium-entry blockers is associated with enhanced tissue protective properties. Positive results with bepridil in hypoxic myocytes and ischemic myocardium distinguishes this drug from the classical antianginal agents verapamil, nifedipine, and diltiazem. It is suggested that bepridil, because of its paucity of hemodynamic effects, may be of special therapeutic interest in the management of silent ischemia where cellular mechanisms leading to cytoprotection are more desirable than strong hemodynamic activity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Physiol. 1980 Aug;239(2):H163-71 - PubMed
    1. Br J Pharmacol. 1986 Nov;89(3):603-12 - PubMed
    1. J Clin Invest. 1984 Sep;74(3):812-20 - PubMed
    1. J Pharmacol Exp Ther. 1984 Sep;230(3):737-41 - PubMed
    1. J Mol Cell Cardiol. 1987 May;19 Suppl 2:19-47 - PubMed

LinkOut - more resources